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ABSTRACT  
Monoacylglycerol lipase (MAGL) is a serine hydrolase that plays an important role in the degradation 
of the endocannabinoid neurotransmitter 2-arachidonoylglycerol, which is implicated in many 
physiological processes. Beyond the possible utilization of MAGL inhibitors as anti-inflammatory, 
anti-nociceptive and anti-cancer agents, their application has encountered obstacles due to the 
unwanted effects caused by the irreversible inhibition of this enzyme. The possible application of 
reversible MAGL inhibitors has only recently been explored, mainly due to the deficiency of known 
compounds possessing efficient reversible inhibitory activities. In this work, we report a new series 
of reversible MAGL inhibitors. Among them, compound 26 showed to be a potent MAGL inhibitor 
(IC50 = 0.51 µM, Ki = 412 nM) with a good selectivity versus fatty acid amide hydrolase (FAAH), 
α/β-hydrolase domain-containing 6 (ABHD6) and 12 (ABHD12). Interestingly, this compound also 
possesses antiproliferative activities against two different cancer cell lines and relieves the 
neuropathic hypersensitivity induced in vivo by oxaliplatin. 
 
INTRODUCTION 
The endocannabinoid system is characterized by a set of neuromodulatory lipids and their receptors, 
which are involved in a multiplicity of physiological and pathological conditions. Two different types 
of G protein-coupled receptors (GPCRs) have been discovered and named as central cannabinoid 
(CB1) and peripheral cannabinoid (CB2) receptors.
1 Endocannabinoid signaling regulates various 
phases of mammalian physiological processes, including pain perception, feeding, emotional state, 
learning and memory.2-4 Endocannabinoids are hypothesized to act as retrograde messengers, where 
stimulation of the postsynaptic neuron activates the biosynthesis of endocannabinoids, which are 
released and transported to activate CB1 receptors expressed mainly in the CNS on the presynaptic 
terminal.5 Endocannabinoids are biosynthesized on demand from phospholipid precursors at the 
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plasma membrane levels and then released in the extracellular milieu.6 After activating the receptors, 
endocannabinoids are transported into the cytoplasm via facilitated diffusion and degraded by specific 
enzymes. Several evidence in vitro and in vivo support the existence of a putative endocannabinoid 
membrane transporter which mediates the bidirectional movement of endocannabinoids through the 
plasma membrane7, 8 in cooperation with other proteins such as hydrolytic enzymes and intracellular 
carrier proteins.9, 10 The complex enzymatic cascades that regulate endocannabinoid production and 
inactivation include different hydrolytic enzymes, such as the fatty acid amide hydrolase (FAAH), N-
acylethanolamine hydrolyzing acid amidase (NAAA) and monoacylglycerol lipase (MAGL).3, 11 The 
selective diacylglycerol lipases (DAGL) α and β are thought to catalyze the formation of 2-
arachidonoylglycerol (2-AG), and MAGL degrades this compound into arachidonate and glycerol. 
Anandamide (AEA) is a partial CB1 agonist and a weak partial CB2 agonist, whereas 2-AG acts as a 
full CB2 agonist.
12 The 2-AG levels in the brain are about three orders of magnitude higher than AEA 
levels, although the relevance of this difference on their signaling actions is still uncertain, mainly 
taking into consideration that their basal extracellular levels, as measured by in vivo microdialysis, 
are within 2- to 5-fold.13, 14 In addition to extracellular CB receptors, endocannabinoids interact with 
other receptors like the vanilloid receptor 1 (VR1), the transient potential vanilloid type 1 channels 
(TRPV1) and other specific GPCRs such as opioid or GPR55 and GPR35 receptors.15 The discovery 
that the endocannabinoids work together with different receptor sites has contributed to the 
identification of this signaling system as a flexible tool to control diverse functions in the cells and 
tissues of the organism. Numerous studies suggest the potential use of selective inhibitors implicated 
in enzymatic degradation of endocannabinoids that could provide selective therapeutic chances.16 To 
reduce the problems connected with CB1 agonists, an amplification of the actions of AEA and 2-AG 
by inhibiting their enzymatic degradation has emerged as a potential strategy to develop the 
endocannabinoid system for medicinal purposes. Pharmacological inhibition of FAAH and MAGL 
was found to decrease pain, inflammation, anxiety, and depression in rodent models without the 
undesired side effects in motility and behavior observed with direct CB1 agonists.
3 First generation 
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MAGL inhibitors include URB602 (compound 1), N-Arachidonoyl maleimide (NAM, compound 2), 
and OMDM169 (compound 3).17 Carbamate compound 1 (Figure 1) was reported as a MAGL 
inhibitor with relatively low potency (IC50 = 28 μM)18 and it was shown to be equally potent against 
FAAH in vitro.19, 20 Furthermore, its administration was shown to attenuate nociception in rodent 
models of acute, inflammatory, and neuropathic pain.21, 22 Compound 2 (Figure 1) is an irreversible 
MAGL inhibitor (IC50 = 140 nM) that was found to decrease 2-AG hydrolase activity of rat cerebellar 
membranes.23 NAM is not selective due to its chemically reactive maleimide functional group that 
will likely react with many cysteine-containing proteins in vivo, thus limiting its use in physiologic 
studies. Another carbamate-based derivative 3 (OMDM169, Figure 1) is a MAGL competitive 
inhibitor (IC50 = 0.89 μM)24 that increased the 2-AG levels at the site of formalin-induced paw 
inflammation but it also inhibited pancreatic lipase and DAGL-α, because of its structural similarity 
with tetrahydrolipstatin. Selective pharmacological tools able to interrupt the in vivo MAGL activity 
have only become accessible within the last few years. By now, they have been used to demonstrate 
the role of this enzyme in 2-AG signaling termination and the potential translational use of targeting 
MAGL in the treatment of nervous system disorders such as pain, anxiety, drug addiction, nausea, 
and neuroinflammation.25-27 Furthermore, MAGL is upregulated in aggressive cancer cells and 
primary tumors and its inhibition in aggressive breast, ovarian and melanoma cancer cells impairs 
cell migration, invasiveness and tumorigenicity.28 Confirmation of MAGL as the primary brain 2-AG 
hydrolase was achieved by the generation of a selective and in vivo active MAGL inhibitor, JZL184 
(4, Figure 1). This piperidine carbamate is a potent and selective MAGL inhibitor (IC50 = 8 nM) that 
when administered to mice, elevated brain 2-AG levels leading to several cannabinoid-related 
behavioral effects.29 Almost all the reported compounds are characterized by an irreversible MAGL 
inhibition mechanism and as reported by Scholsburg et al., the irreversible inhibition of MAGL 
produces cross-tolerance to CB1 agonists in mice after repeated administrations.
30 Furthermore, 
chronic MAGL blockade causes physical dependence, impairs endocannabinoid-dependent synaptic 
plasticity and desensitizes brain CB1 receptors.
30 Considering these drawbacks associated with an 
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irreversible MAGL inhibition, the development of reversible inhibitors could represent a promising 
alternative strategy; however, their use has been investigated only partially so far, mainly because of 
the lack of compounds with good MAGL reversible inhibition properties. In 2012 Cisneros et al. 
reported a series of oxirane derivatives characterized by a dual MAGL/FAAH reversible inhibition 
activity;31 whereas in 2014 Hernandez-Torres et al. reported the reversible MAGL inhibitor 
benzo[d][1,3]dioxol-5-ylmethyl 6-([1,1′-biphenyl]-4-yl)-hexanoate 5 (compound c21, Figure 1). 
Interestingly, this compound was also tested in vivo and its therapeutic effects were not accompanied 
by catalepsy or other motor impairments that have been observed instead after the administration of 
irreversible MAGL inhibitors.32 In 2015 Patel et al. developed a series of Loratadine analogues that 
showed potent and reversible inhibition of MAGL, accompanied also by selectivity towards human 
FAAH. Furthermore, one of these derivatives proved to possess antagonistic activity towards the 
Histamine H1 receptor and showed selectivity against cannabinoid receptors, α/β-hydrolase domain-
containing 6 (ABHD6) and α/β-hydrolase domain-containing 12 (ABHD12).33 Finally, very recently 
Granchi et al. reported a benzoylpiperidine derivative characterized by a good MAGL inhibitory 
activity (IC50 = 0.84 µM) and a reversible mechanism of inhibition.
34  
 
Figure 1. Representative MAGL inhibitors. 
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In the present study, we report the development of a diphenylpyrazole series as a new class of MAGL 
reversible inhibitors.  
RESULTS AND DISCUSSION 
From the analysis of the main available data concerning MAGL reversible inhibition,34-36 some 
pharmacophoric elements seem to be important for inhibitory activity: a) a carbonyl group able to 
interact into the oxyanion hole of the enzyme, b) an aromatic portion comprising also an heterocyclic 
nucleus, involved in van der Waals interactions in a closed hydrophobic region of the binding site 
(red region of Figure S1) and c) a second aromatic portion which interacts in the open large 
hydrophobic cavity of MAGL (green region of Figure S1). Following this binding analysis, we 
hypothesized that the 1,5-diphenylpyrazole scaffold, properly substituted with a carbonyl group and 
different fragments, could represent the starting point for the identification of new reversible MAGL 
inhibitors. Following these indications, we synthesized three different diphenylpyrazole derivatives 
(6-8, Table 1) characterized by different substituents. The compounds were thus tested for their 
MAGL inhibition activity together with the CAY10499 derivative,37 which was used as a reference 
compound. As shown in Table 1, the (5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-
2-yl)piperazin-1-yl)methanone (8) showed an appreciable activity with an IC50 value of 6.8 µM, 
whereas the other two compounds were inactive. 
 
Table 1. MAGL inhibitory activities of diphenylpyrazole derivatives. 
compd Structure IC50 (µM) 
6 
 
>> 200 
7 
 
7 
 
>> 200 
8 
 
6.8 ± 0.4 
CAY10499 
 
0.14 ± 0.02 
 
As shown in Figure 2, the docking results for this compound highlight the presence of two H-bonds 
between the carbonyl oxygen of the compound and the nitrogen backbone of A51 and M123 in the 
oxyanion hole. The piperazinylpyrimidine fragment is inserted into the closed hydrophobic region of 
the binding site and shows lipophilic interactions with I179, L184, V270 and a π-π interaction with 
Y194. The N-phenyl ring shows lipophilic interactions with L148, A151, L213 and L241, whereas 
the 5-phenol ring shows lipophilic interactions with L205 and a weak H-bond with S176. 
 
 
Figure 2. Docking of compound 8 into MAGL. 
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Using this compound as a starting hit, a first round of structural investigation has been carried out by 
maintaining the central pyrazole core fixed and varying: 1) the substituent present on the nitrogen 
atom (phenyl or methyl group) of the pyrazole ring (R2, Table 2); 2) the portion linked to the carbonyl 
group in position 3 of the pyrazole ring (R3, Table 2) and 3) the position of the hydroxyl group of the 
phenolic ring in position 5 (R1, Table 2). As shown in Table 2, the substitution of the 1-phenyl ring 
with a methyl group determined an important decrease of activity (compound 9) compared to 8, as 
well as the shift of the p-hydroxy group to the meta position (compound 10). The replacement of the 
pyrimidine with a phenyl ring determined a slight increase of activity (11, IC50 = 4.7 µM), but when 
a benzyl group was inserted in place of the phenyl the activity was about two-fold lower (14, IC50 = 
12 µM). When pyrimidine was replaced with a methyl group (12) or the entire piperazinylpyrimidine 
fragment with a morpholine ring (13) a ten-fold decrease of activity was observed. Conversely, the 
best result was achieved by the replacement of the piperazinylpyrimidine with the 4-benzylpiperidine, 
which led to a 3.5 fold increase of the activity (15, IC50 = 2.0 µM). Finally, the replacement of the 4-
benzylpiperidine with larger dimension groups such as the 1-benzylpiperidin-4-amine of compound 
16 and the 2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethanamine of compound 17 led to a completely loss 
of activity. 
 
Table 2. MAGL inhibitory activities of 8 derivatives. 
 
compd R1 R2 R3 IC50 (µM) 
9 
 
8 4-OH 
  
6.8 ± 0.4 
9 4-OH -CH3 
 
132 ± 20 
10 3-OH 
  
48 ± 2 
11 4-OH 
  
4.7 ± 0.1 
12 4-OH 
  
71 ± 3 
13 4-OH 
  
61 ± 15 
14 4-OH 
 
 
12 ± 1 
15 4-OH 
 
 
2.0 ± 0.1 
16 4-OH 
 
 
>> 200 
17 4-OH 
 
 
>> 200 
 
As shown in Figure 3, with respect to the piperazinylpirimidine of derivative 8, the 4-benzylpiperidine 
of 15 is inserted deeper inside the closed hydrophobic region of the binding site and shows stronger 
lipophilic interactions with L184, V270 and the π-π interaction with Y194. This different disposition 
determines also a slight different orientation of the 5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazole 
fragment with the formation of an H-bond between the hydroxyl group and the oxygen backbone of 
P178.  
10 
 
 
 
Figure 3. Docking of compound 15 (green) into MAGL. Compound 8 (cyan) is displayed as a 
reference compound. 
 
In order to verify the role of the p-hydroxyl in the binding process, this group was removed or replaced 
with a chlorine atom. As shown in Table 3, in both cases (compounds 19 and 18), the compounds 
showed a decrease of MAGL inhibitory activity (IC50 value of 13 and 11 µM, respectively), 
supporting the possible attractive interaction of the p-hydroxy group with the enzyme, as suggested 
by modeling studies. The comparison between the disposition of compounds 8 and 15 suggests that 
the phenyl ring of 15 bound to the nitrogen atom in position 1 of the pyrazole ring appears to be 
shifted towards the central region of the open binding cavity and could have weaker lipophilic 
interactions with L148, A151 and L241, when compared to the phenyl ring of analogue 8. On these 
bases, the phenyl ring of 15 was substituted with different groups, such as the p-methoxy (20), p-
chloro (21) and p-methyl (22) and with different aromatic portions such as the benzyl (23), 
phenylethyl (24) and phenylpropyl (25) fragments. The enzymatic assays revealed that the 
introduction of the benzyl group such as in compound 23 determined the highest increase of inhibitory 
activity (IC50 = 0.81 µM, Table 3). Then, in order to maximize the lipophilic interactions of this 
fragment, methyl groups in para and meta position of the benzyl moiety were introduced (26, 27 and 
28). Finally, a naphtylmethyl group (29) was inserted in the place of the benzyl group. As shown in 
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Table 3, the meta-methyl substitution of the benzyl ring determined a further slight improvement of 
the MAGL inhibitory activity, with a resulting IC50 of 0.51 µM (compound 26). 
 
Table 3. MAGL inhibitory activities of 4-benzylpiperidines (compound 15 derivatives). 
 
compd R1 R2 IC50 (µM) 
18 Cl 
 
11 ± 3 
19 H 
 
13 ± 1 
20 OH 
 
3.2 ± 0.1 
21 OH 
 
1.4 ± 0.2 
22 OH 
 
1.5 ± 0.1 
23 OH 
 
0.81 ± 0.02 
24 OH 
 
4.3 ± 0.4 
25 OH 
 
1.6 ± 0.1 
26 OH 
 
0.51 ± 0.03 
27 OH 
 
1.1 ± 0.1 
12 
 
28 OH 
 
1.4 ± 0.1 
29 OH 
 
1.6 ± 0.3 
 
As shown in Figure 4, the binding disposition of compound 26 is very similar to that observed for 15, 
maintaining the lipophilic interactions of the 4-benzylpiperidine with L184, V270 and the π-π 
interaction with Y194, the interaction of the carbonyl group in the oxyanion hole and the H-bond 
between the p-hydroxyl group and the oxygen backbone of P178. Differently from 15, the m-
methylbenzyl fragment points towards the surface of the binding site and shows stronger lipophilic 
interactions with in particular A151 and L241. 
 
 
Figure 4. Docking of compound 26 (orange) into MAGL. Compound 8 (cyan) is displayed as a 
reference compound. 
 
With the aim of evaluating the reversible or irreversible mechanism of inhibition, the effects of 
dilution and preincubation on the inhibitory ability of compound 26 were evaluated. In the dilution 
experiments, in case of an irreversible inhibition, the potency should not decrease after dilution. 
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Differently, in case of a reversible inhibition, the potency level should be substantially reduced after 
dilution.38 In our experiment, the inhibition produced by preincubation with a 20 µM concentration 
of 26 was measured after a 40X dilution and compared to the potency observed by a 20 µM and a 0.5 
µM of compound 26. As shown in Figure 5A, 26 showed a reversible inhibition mechanism, as the 
inhibition produced by 0.5 µM of the compound was similar to that of 40X dilution, and was different 
to that produced by the compound at a concentration of 20 µM. As a second test, the activity of 26 
was assayed at different preincubation times of the compound with MAGL. In this assay, the 
compound is incubated with the enzyme 30 and 60 minutes before the addition of the substrate and 
the observed IC50 is then compared with that obtained without a preincubation of the compound with 
the enzyme. An irreversible inhibitor will show a higher potency with a higher incubation time 
whereas a reversible inhibitor will show a constant inhibition potency independent from the 
incubation time. As shown in Figure 5B, this assay confirmed the reversible property of 26, as it did 
not show any significant increase in inhibition potency with different incubation times. 
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Figure 5. Compound 26-MAGL inhibition analysis. A) Dilution assay: the first two columns indicate 
the inhibition percentage of compound 26 at a concentration of 20 µM and 0.5 µM. The third column 
indicates the inhibition percentage of compound 26 after dilution (final concentration = 0.5 µM). B) 
IC50 (µM) values of 26 at different preincubation times with MAGL (0 min, 30 min and 60 min). 
 
Once confirmed the reversible mechanism of compound 26, its inhibition mode was then determined 
by evaluating Michaelis-Menten kinetics with various inhibitor concentrations. The dataset was 
plotted as substrate concentration versus MAGL activity and evaluated by using the mixed-model 
inhibition fit of GraphPad Prism 5.0, thus including competitive, uncompetitive, and noncompetitive 
inhibition terms. This analysis produces the Vmax, Km, Ki and the α value, a parameter consisting of a 
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positive number (α is always greater than zero) that can be used as an indicator of the mechanism of 
inhibition. In fact, when α is smaller than one, then the mixed model becomes nearly identical to an 
uncompetitive model; when it is equal to one, then the mixed-model is identical to a noncompetitive 
inhibition; finally, when α has a very large value, then the mixed-model becomes identical to a 
competitive inhibition. As shown in Figure 6, the Michaelis-Menten-type curve resulted in Km values 
of 0.21 ± 0.07 mM, Vmax value of 42 ± 1 µmol•(min-1mg-1), a Ki value for 26 of 412 ± 19 nM and an 
α value greater than 100000, thus supporting a competitive behavior for the selected compound. 
 
 
Figure 6. Inhibition of the activity of MAGL and competitive nature of compound 26. 
 
Selectivity analysis. With the aim of evaluating the selectivity of compound 26 versus the other major 
endocannabinoid degrading enzymes, its activities against FAAH, ABHD6 and ABHD12 were tested. 
As shown in Table 4, compound 26 did not show any significant inhibition of FAAH and ABHD12 
at the concentration of 10 M (7% and 32% of inhibition for FAAH and ABHD12, respectively), 
while ABHD6 was actually inhibited with an IC50 value of 7.1 ± 2.3 µM. Thus compound 26 behaves 
as MAGL inhibitor showing good selectivity over FAAH, ABHD6 and ABHD12 (see the 
Experimental section for details). Finally, since the diarylpyrazoles are a well-known class of 
cannabinoid receptor ligands,39 the possible affinities of compound 26 for the cannabinoid receptors 
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CB1 and CB2 were also evaluated. As reported in Table 4 this compound did not show a significant 
binding to any of the two cannabinoid receptor subtypes.  
 
Table 4. Biological activity of compound 26 on the major components of the endocannabinoid 
system. Effects on FAAH, ABHD6, ABHD12, CB1 and CB2 receptors are expressed as IC50 value 
(mean ± SD, µM). In bracket the % enzymatic inhibition (FAAH and ABHD12) or receptor binding 
(CB1 and CB2 receptors) at 10 μM is reported.  
compd FAAH ABHD6 ABHD12 CB1 binding CB2 binding 
26 > 10 (7%) 7.1 ± 2.3 > 10 (32%) > 10 (22%) > 10 (35%) 
 
Antiproliferative assays. Compound 26 was further tested in in vitro experiments to evaluate its 
antiproliferative potency against cancer cells, together with compound CAY10499, which was used 
as the reference compound. As suggested by literature data, MAGL is an optimal candidate target for 
ovarian cancer.28 Western blot analysis has recently highlighted that MAGL is overexpressed in 
OVCAR3 and CAOV3 compared to OVSAHO and COV318 cell lines.34 These cell lines were 
selected since they represent more closely high-grade serous ovarian cancer (HG-SOC),40 a fatal 
tumor. At the molecular level, all cell lines are mutated in the TP53 gene, BRCA2 gene (OVSAHO) 
or the cell cycle pathway (OVSAHO, COV318, OVCAR3), which are common events in HG-SOC. 
Therefore, the antiproliferative activity of the two compounds was tested against these four cell lines, 
together with the noncancerous human fibroblast lung cells (MRC5). As shown in Table 5, compound 
26 caused a good inhibition of cell viability, with IC50 values of 12 and 11 μM in the OVCAR3 and 
CAOV3 cell lines, respectively, whereas it proved to be about 7-fold less potent against ovarian 
cancer cells that do not overexpress MAGL, such as OVSAHO and COV318 cells. Furthermore, 26 
proved to be inactive also against noncancerous human fibroblast lung cells (MRC5, IC50 > 100 μM). 
The covalent reference inhibitor CAY10499 showed inhibition of cell viability in all the four ovarian 
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cancer cell lines, with IC50 values ranging from 23 to 77 μM without any significant discrimination 
between the two MAGL-overexpressing cell lines OVCAR3 and CAOV3 and the other two lines, 
OVSAHO and COV318.  
 
Table 5. Cell growth inhibitory activities (IC50) of compounds 24 and CAY10499. 
 IC50 values (µM) 
 OVSAHO OVCAR3 COV318 CAOV3 MRC5 
26 90 ± 6 12 ± 2 78 ± 6 11 ± 1 > 100 
CAY10499 23 ± 2 43 ± 6 59 ± 4 77 ± 7 > 100 
 
Antinociceptive effects of 26 in animal model of neuropathic pain. The effect of 26 was evaluated 
in a mouse model of nociceptive behavior caused by the chemotherapeutic agent, oxaliplatin (cold 
plate test). The pain threshold measurements of oxaliplatin-treated animals are shown in Figure 7. 
The cold plate test allows to evaluate the response to a thermal non noxious stimulus defined as 
allodynia-like. On day 15, oxaliplatin decreased the licking latency to 10.0 ± 0.5 s in comparison to 
control mice (17.6 ± 0.4 s). A single treatment p.o. with 26 relieved pain dose-dependently. The lower 
dose of 10 mg/kg induced a significant effect 30 min after the administration. At 30 mg/kg the 
compound reduced oxaliplatin-induced neuropathic pain 30 and 45 min after treatment and in 
particular, after 30 min it increased pain threshold to a value similar to that shown by control animals 
(vehicle + vehicle). 
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Figure 7. Effect of 26 on oxaliplatin-induced neuropathic pain. Oxaliplatin (2.4 mg/kg) was dissolved 
in 5% glucose solution and administered i.p. on days 1-2, 5-9, 12-14. On day 15, 26 (10 and 30 mg/kg) 
was suspended in carboxymethylcellulose (CMC) and p.o. administered. Pain-related behavior (i.e. 
lifting and licking of the hind paw) was observed by the cold plate test and the time (s) of the first 
sign was recorded. **P<0.01 vs Vehicle + Vehicle treated animals; ^P<0.05 and ^^P<0.01 vs 
oxaliplatin + Vehicle group. Each value represents the mean of 10 mice performed in 2 different 
experimental sets. 
 
In order to test the effects of the compound after repeated treatments, 26 (30 mg/kg, p.o.) was co-
administered with oxaliplatin from day 1 to day 14 following the same protocol. Pain threshold was 
evaluated by cold plate test on days 7 and 15, 24 h after the last administration. As shown in Figure 
8 (upper panel), oxaliplatin induced a significant hypersensitivity both the first and the second week. 
Compound 26 significantly reduced cold allodynia on day 7 as well as on day 15. The effect 
progressively increased overtime. On day 15, 24 h after the last administration, mice treated with 26 
showed a complete pain relief. These results highlight: i) the long lasting efficacy of the compound 
after repeated treatments, ii) the increasing activity during treatment, suggesting protective properties 
against oxaliplatin neurotoxicity, iii) the complete lack of tolerance development.  
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Figure 8. Anti-neuropathic pain activity of 26 after subchronic treatment. Oxaliplatin (2.4 mg/kg) 
was dissolved in 5% glucose solution and administered i.p. on days 1-2, 5-9, 12-14. 26 (30 mg/kg) 
was suspended in carboxymethylcellulose (CMC) and administered p.o. using the same protocol as 
that for oxaliplatin alone. The cold plate test was performed 24 h after the last administration on days 
7 and 15 observing the pain-related behavior (i.e. lifting and licking of the hind paw). **P<0.01 vs 
vehicle + vehicle treated animals; ^P<0.05 and ^^P<0.01 vs oxaliplatin + vehicle group. Each value 
represents the mean of 10 mice performed in 2 different experimental sets. 
 
We also quantified by LC-MS/MS the amount of 2-AG, AEA, arachidonic acid, prostaglandin-E2 
(PGE2) and prostaglandin-D2 (PGD2) in brain and spinal cord after 15 days of treatment. Animals 
treated with oxaliplatin and compound 26 did not show any significant difference in 2-AG levels as 
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compared to oxaliplatin-treated mice (see Figure S2). Previous studies reported that covalent MAGL 
inhibitors exert significant anti-allodynic effects in different mouse models of neuropathic pain.41-44 
However, in these animal models MAGL inhibition exerted opposite effects on the modulation of 2-
AG concentrations in brain, spinal cord and dorsal root ganglia (DRGs). For example, Kinsey at al. 
reported a marked increase of 2-AG levels in brain and spinal cord of mice treated with a single 
injection of JZL184 (16 mg/kg, ip) 14 days after chronic constriction injury (CCI) surgery.41 On the 
contrary, Khasabova et al. reported no significant change in 2-AG levels in brain and spinal cord after 
7 days of treatment with cisplatin and JZL184 (10 g, subcutaneous injection).45 In the same study, 
JZL184 was able to recover the cisplatin-induced reduction of 2-AG level in DRGs. Wilkerson et al. 
showed that suprathreshold dose of MJN110 (0.1432 mg/kg, ip) could only marginally increase 2-
AG level in the spinal cord of mice subjected to CCI surgery while not affecting 2-AG level in the 
brain.44 Our data showed that compound 26 did not increase 2-AG levels in brain and spinal cord of 
mice treated for 15 days, despite inducing significant anti-allodynic effects. This may be due to a mild 
and specific increase of 2-AG concentrations in specific brain or spine regions. Alternatively, 
compound 26 may exhibit only a negligible penetration or activity in the central nervous system. 
Previous studies showed that the anti-allodynic effect of FAAH and MAGL inhibitors is associated 
with the modulation of AEA and 2-AG levels in DRGs.45, 46 Thus, we may speculate that the anti-
allodynic effect induced by compound 26 could be associated with the modulation of 2-AG levels in 
the peripheral nervous system (i.e. DRGs). In agreement with this hypothesis, it was shown that the 
disposition of cisplatin is limited to peripheral tissues and DRGs were the most vulnerable neural 
structure.47 However, we cannot exclude the possibility that the in vivo effects showed by compound 
26 may also be dependent by alternative mechanisms beyond MAGL inhibition. 
Chemistry. The diphenylpyrazole compounds 6-29 were prepared as shown in Scheme 1. Claisen 
condensation of commercially available acetophenones 28b-d or 4′-benzyloxyacetophenone 28a48 
(for the preparation of compounds 6 and 7) with diethyl oxalate afforded the corresponding 
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diketoesters 29a-d49 in quantitative yields. Following cyclization with hydrazines gave both the 
corresponding 1,5-disubstituted-pyrazole-3-carboxylic acid esters and the low yield isomer 1,3-
diphenyl-5-carboxylates, which were easily separated by column chromatography on silica gel.50 
Esters 30a-p were converted to the corresponding carboxylic acids 31a-p by treatment with aqueous 
sodium hydroxide. The pyrazole-3-carboxylic acids were converted to the corresponding 
carboxamide derivatives 6-29 via coupling reaction with the appropriate amines. 
 
Scheme 1a 
 
 
aReagents and conditions: (i) Diethyl oxalate, NaH, THF, reflux, 1 h; (ii) appropriate hydrazine, 
absolute EtOH, 80 °C, 5 h; (iii) NaOH aq (10%), ethanol, reflux, 60 °C, 4 h; (iv) appropriate amine, 
EDCI, HOBt, DMF, rt, 16 h. 
22 
 
 
CONCLUSIONS 
In the present work we have reported a new class of MAGL reversible inhibitors. Starting from (5-
(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone (8) a 
structural optimization has been performed leading to the identification of compound 26, which 
displayed a high MAGL inhibition activity with a Ki of 412 nM. This reversible inhibitor was then 
tested in cell-based assays where it showed promising cell growth inhibitory activities in an 
antiproliferative assay in the OVCAR-3 and CAOV3 cell lines that overexpress MAGL. Furthermore, 
oral administration of 26 dose dependently reversed the lowering of the threshold to cold stimuli (cold 
plate test) induced by oxaliplatin, indicating its efficacy in the treatment of neuropathic pain. The 
efficacy increased after repeated administration suggesting a possible protective effect in the absence 
of tolerance development, even if evidences about the in vivo actual inhibition of MAGL after 
administration of the compound are needed. Taken together these results suggest that these new 
compounds could open new perspectives for developing novel reversible MAGL inhibitors.  
EXPERIMENTAL SECTION 
Pan Assay Interference Compounds (PAINS) analysis. In order to exclude the possibility that the 
herein reported class of compounds could act as artifacts or promiscuous bioactive molecules, a 
PAINS analysis for the most active compound (26) was carried out.51 
PAINS substructural features screening. As reported by Baell and Holloway there is a number of 
substructural features which could help to identify compounds that appear as PAINS in many 
biochemical high throughput screens.52 The corresponding filters have been included in the Filter-
itTM software and compound 26 was thus filtered by using this program. The result highlighted that 
this compound did not possess any of the substructural features shared by the most common PAINS. 
Interference analysis. Some PAINS are associated with color that could interfere photometrically 
with the assay. In order to avoid this possibility for each compound concentration a blank analysis 
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was carried out, and the final absorbance values were obtained subtracting the absorbance determined 
by the presence of all the components except the enzyme in the same conditions.  
Aggregation analysis. In order to exclude possible aggregation behaviors, all the enzymatic assays 
were carried out in the presence of bovine serum albumin (BSA) 0.1 mg/ml.  
Thiol reactive analysis. In some cases, PAINS properties could be caused by a covalent interaction 
between a ligand and cysteines of multiple proteins. 53 In order to investigate this possibility, the 
inhibition activity of 26 against MAGL was tested in the presence of the thiol-containing agent 1,4-
dithio-DL-threitol (DTT).54 This assay suggested that the inhibition potency of 26 was not affected by 
the presence of DTT, as it showed an IC50 = 0.50 ± 0.04 µM when assayed with 100 M DTT, thus 
excluding the interaction of this compound with the cysteine residues of the MAGL enzyme. 
Selectivity testing. As reported by Dahlin and Walters55 a selectivity analysis is another test that 
would contribute to highlight most PAINS. As reported in the text we measured the activity of 
compound 26 against FAAH, ABHD6 and ABHD12 resulting in a good MAGL selectivity.  
Orthogonal assay. The application of a different readout method for measuring the activity against 
the target is another step that contribute to elucidate the PAINS properties. For this reason the activity 
of 26 against MAGL was also tested by using an HPLC/UV assay.56 An aliquot of stock solutions of 
MAGL was diluted 1:125 with Tris buffer (pH = 7.2; 10 mM, containing 1.0 mM EDTA) to obtain 
the working solutions of MAGL at 1.6 ng/µl. The stock and working solutions were stored at −20 °
C. In a 0.5 ml spin tube containing 75 µl of Tris buffer (pH = 7.2; 10 mM containing 1.0 mM EDTA), 
5 µl of working solution MAGL (8 ng), 5 µl inhibitor (or solvent as control) and 5 µl of a solution of 
4-nitrophenylacetate (4-NPA) substrate in absolute ethanol (4.25 mM) were added. Samples were 
incubated for 10 min, then the enzymatic reaction was stopped by cooling in an ice bath for 10 min 
and 20 µl of the reaction mixture were taken and analyzed by HPLC. Shimadzu Prominence HPLC 
system was used to quantify 4-nitrophenol formed after enzymatic hydrolysis of 4-NPA by using a 
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diode-array detector at operation wavelength of 310 nm. Separation of compounds was carried out 
on a Kinetex EVO C18 column (5 μm, 150 mm × 4.6 mm, Phenomenex, Inc.). The mobile phase, 
delivered at a flow rate of 1.0 ml/min and consisted of methanol and ammonium acetate buffer (pH 
4.0; 10 mM) (53:47, v/v). The sample injection volume was 20 µl. Data were monitored and analyzed 
using chromatography Software LabSolutions Lite (Shimadzu). By using this assay method, 
compound 26 showed an IC50 against MAGL of 0.39 ± 0.05 µM, thus confirming the inhibition 
activity measured by the colorimetric assay. 
Docking Calculations. The crystal structure of human MAGL (pdb code 3PE635) was minimized 
using Amber14 software57 and ff14SB force field at 300 K. The TIP3P explicit solvent model for 
water, was used with a 10 Å water cap. In order to neutralize the system, sodium ions were added. 
Two minimization steps of were performed; in the first stage, the protein was kept fixed with a 
position restraint of 500 kcal/mol Å2 minimizing the positions of the water molecules. In the second 
stage, the entire system was minimized through 5000 steps of steepest descent followed by conjugate 
gradient (CG) until a convergence of 0.05 kcal/Å•mol. The ligands were built using Maestro58 and 
were minimized by means of Macromodel59 in a water environment using the CG method using the 
MMFFs force field. Docking analysis was performed by means of the AUTODOCK 4.0 program;60 
Autodock Tools61 was used in order to identify the torsion angles in the ligands, add the solvent model 
and assign the Kollman atomic charges to the protein. The ligand charge was calculated using the 
Gasteiger method. The ZYH reference inhibitor was used in order to identify the binding site; a grid 
of 82, 40, and 30 points in the x, y, and z directions was constructed centered on the center of the 
mass of this compound. A grid spacing of 0.375 Å and a distance-dependent function of the dielectric 
constant were used for the energetic map calculations. Using the Lamarckian Genetic Algorithm, the 
docked compounds were subjected to 100 runs of the Autodock search, using 500000 steps of energy 
evaluation and the default values of the other parameters. Cluster analysis was performed on the 
results using an RMS tolerance of 2.0 Å.  
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MAGL inhibition assay. Human recombinant MAGL, CAY10499 and 4-NPA substrate were from 
Cayman Chemical. The enzymatic reaction was carried out at room temperature (final volume of 200 
μL in 10 mM Tris buffer, pH 7.2, containing 1 mM EDTA and 0.1 mg/ml BSA). A total of 150 μL 
of 4-NPA 133.3 μM (final concentration = 100 μM) was added to 10 μL of DMSO containing the 
appropriate amount of compound and the reaction was initiated by the addition of 40 μL of MAGL 
(11 ng/well). The final concentration of the analyzed compounds ranged for CAY10499 from 10 to 
0.00001 μM and for the other compounds from 200 to 0.0128 μM. After the reaction had proceeded 
for 30 min, absorbance values were then measured by using a Victor X3 Microplates Reader 
(PerkinElmer®) at 405 nm.37 The assay was generated in 96-well microtiter plates. Two reactions 
were also run: one reaction containing no compounds and the second one containing neither inhibitor 
nor enzyme. IC50 values were derived from experimental data using the Sigmoidal dose−response 
fitting of GraphPad Prism software. To remove possible false positive results, for each compound 
concentration a blank analysis was carried out, and the final absorbance results were obtained 
detracting the absorbance produced by the presence of all the components except MAGL in the same 
conditions. In the enzyme kinetics experiments, compound was tested in the presence of scalar 
concentrations of 4-NPA. It was added in scalar amounts (concentration range = 1–8 μM) to a reaction 
mixture containing Tris buffer and scalar concentrations of 4-NPA (15–1400 μM). Finally, MAGL 
solution was added (11 ng/well). The MAGL activity was measured by recording the increase in 4-
nitrophenol absorbance using the Victor X3 Microplates Reader (PerkinElmer®). The experimental 
data were analyzed by non-linear regression analysis with GraphPad Prism software, using a second 
order polynomial regression analysis, and by applying the mixed-model inhibition fit. 
FAAH inhibition assay. Human recombinant FAAH and AMC arachidonoylamide substrate were 
from Cayman Chemical. The FAAH reaction was conducted at room temperature (final volume of 
200 μL in 125 mM Tris buffer, pH 9.0, containing 1 mM EDTA and 0.1 mg/ml BSA). A total of 150 
μL of AMC arachidonoylamide 13.3 μM (final concentration = 10 μM) was added to 10 μL of DMSO 
containing the appropriate amount of compound. The reaction was initiated by the addition of 40 μL 
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of FAAH (0.9 µg/well) in such a way that the assay was linear over 30 min. The final concentration 
of the analyzed compounds ranged for from 200 to 0.0128 µM. After the reaction had proceeded for 
30 min, fluorescence values were then measured by using a Victor X3 PerkinElmer instrument at an 
excitation wavelength of 340 nm and an emission of 460 nm. As for MAGL assay, two reactions were 
also run: one reaction containing no compounds and the second one containing neither inhibitor nor 
enzyme. IC50 values were derived from experimental data using the Sigmoidal dose−response fitting 
of GraphPad Prism software. To remove possible false positive results, for each compound 
concentration a blank analysis was carried out, and the final fluorescence results were obtained 
detracting the fluorescence produced by the presence of all the components except FAAH in the same 
conditions. Furthermore, compound 26 was also tested for FAAH inhibition using mouse brain 
homogenate as previously reported.8 
CB1 and CB2 receptor binding assays. Receptor binding experiments were performed with 
membrane preparations as previously reported.62 Briefly, clean membranes expressing hCB1 or hCB2 
were re-suspended in binding buffer (50 mM Tris-HCl, 2.5 mM EDTA, 5 mM MgCl2, 0.5%
1 fatty 
acid-free bovine serum albumin (BSA), pH 7.4) and incubated with vehicle or compounds and 0.5 
nM of [3H]CP55,940 for 90 min at 30 °C. Non-specific binding was determined in the presence of 10 
μM of WIN55,512. After incubation, membranes were filtered through a pre-soaked 96-well 
microplate bonded with GF/B filters under vacuum and washed twelve times with 150 μL of ice-cold 
binding buffer. The radioactivity was measured and the results expressed as [3H]CP55,940 binding. 
ABHD6 and ABHD12 inhibition assay. ABHDs activity assays were performed as previously 
described.8 The hABHD6 and hABHD12 activity was determined using cell homogenates from 
hABHD6 and hABHD12 stably transfected HEK293 cells. Compound was pre-incubated with 40 μg 
of cell homogenate for 30 min at 37 °C in assay buffer (Tris 1 mM, EDTA 10 mM plus 0.1% BSA, 
pH= 7.6). DMSO was used as vehicle control and WWL70 10 μM or THL 20 μM as positive controls. 
Then, 10 μM of 2-OG was added and incubated for 5 min at 37 ºC. The reaction was stopped by the 
addition of 400 μL of ice-cold CHCl3:MeOH (1:1). The samples were vortexed and centrifuged 
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(16000 x g, 10 min, 4 ºC). Aliquots (200 μL) of the aqueous phase were assayed for tritium content 
by liquid scintillation spectroscopy. Blank values were recovered from tubes containing no enzyme. 
Basal 2-OG hydrolysis occurring in non-transfected HEK293 cells was subtracted. 
Cell viability assay. OVSAHO, OVCAR3, COV318, CAOV3 and MRC5 (from ATCC) were 
maintained at 37 °C in a humidified atmosphere containing 5% CO2 accordingly to the supplier. 
Normal (1.5 × 104) and tumor (5 × 102) cells were plated in 96-well culture plates. The day after 
seeding, vehicle or compounds were added at different concentrations to the medium. Compounds 
were added to the cell culture at a concentration ranging from 100 to 0.01 µM. Cell viability was 
measured after 96 h according to the supplier (Promega, G7571) with a Tecan F200 instrument. IC50 
values were calculated from logistical dose response curves. Averages were obtained from three 
independent experiments, and error bars are standard deviations (n = 3). 
Animals. Male CD-1 albino mice (Envigo, Varese, Italy) weighing approximately 22–25 g at the 
beginning of the experimental procedure, were used. Animals were housed in CeSAL (Centro 
Stabulazione Animali da Laboratorio, University of Florence) and used at least 1 week after their 
arrival. Ten mice were housed per cage (size 26 × 41 cm); animals were fed a standard laboratory 
diet and tap water ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at 7 a.m. All 
animal manipulations were carried out according to the European Community guidelines for animal 
care (DL 116/92), application of the European Communities Council Directive of 24 November 1986 
(86/609/EEC). The ethical policy of the University of Florence complies with the Guide for the Care 
and Use of Laboratory Animals of the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996; University of Florence assurance number: A5278-01). Formal approval to conduct the 
experiments described was obtained from the Animal Subjects Review Board of the University of 
Florence. Experiments involving animals have been reported according to ARRIVE guidelines. All 
efforts were made to minimize animal suffering and to reduce the number of animals used. 
Oxaliplatin-induced neuropathic pain model. Mice treated with oxaliplatin (2.4 mg/kg) were 
administered i.p. on days 1-2, 5-9, 12-14 (10 i.p. injections)63, 64 oxaliplatin was dissolved in 5% 
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glucose solution. Control animals received an equivalent volume of vehicle. Behavioral tests were 
performed on day 15. 
Cold plate test. The animals were placed in a stainless steel box (12 cm × 20 cm × 10 cm) with a 
cold plate as floor. The temperature of the cold plate was kept constant at 4 °C ± 1 °C. Pain-related 
behavior (licking of the hind paw) was observed and the time (seconds) of the first sign was recorded. 
The cut-off time of the latency of paw lifting or licking was set at 60 seconds.65  
LC-MS/MS quantification of endocannabinoids and other metabolites. The amount of 2-AG, 
AEA, arachidonic acid (AA), prostaglandin-E2 (PGE2) and prostaglandin-D2 (PGD2) were 
measured by LC-MS/MS in brain and spinal cord of mice treated for treated for 14 days with 
oxaliplatin (2.4 mg/kg, i.p.) and compound 26 (30 mg/kg, p.o.) or vehicle. At day 15, animals were 
sacrificed by decapitation 1 h after the last dose and brain and spinal cord were collected, quickly 
washed in PBS and snap-frozen. Tissue extraction and LC-MS/MS conditions were performed as 
previously described.8 
Statistical analysis. Behavioral measurements were performed on 10 mice for each treatment carried 
out in 2 different experimental sets. Results were expressed as mean ± S.E.M. The analysis of variance 
of behavioral data was performed by one way ANOVA, a Bonferroni's significant difference 
procedure was used as post-hoc comparison. P values of less than 0.05 or 0.01 were considered 
significant. Investigators were blind to all experimental procedures. Data were analyzed using the 
“Origin 9” software (OriginLab, Northampton, USA). 
General Procedures and Materials. 1H NMR data were recorded with a Varian VXR 200 
spectrometer or a Varian Mercury Plus 400 spectrometers. Chemical shifts (δ) are reported in parts 
per million, and J values are given in Hertz. Positive ion electrospray ionization (ESI) mass spectra 
were recorded on a double-focusing Finnigan MAT 95 instrument with BE geometry. Melting points 
(mp) were determined on a Buchi-Tottoli apparatus and are uncorrected. Chromatography was 
performed on Merck 230–400 mesh silica gel and a mixture of ethyl acetate and petroleum ether in 
different ratios as mobile phase The purity of tested compounds was determined by combustion 
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elemental analyses in the Microanalytical Laboratory of the Chemistry Department of the University 
of Ferrara with a Yanagimoto MT-5 CHN recorder elemental analyser. All tested compounds yielded 
data consistent with a purity of at least 95% as compared with the theoretical values. TLC was carried 
out using glass plates coated with silica gel 60 F254 by Merck, and compounds were visualized by 
UV lamp (254 nm light source). Organic solutions were dried over anhydrous Na2SO4. Solvents and 
reagents were purchased from Aldrich (Sigma-Aldrich) or Alfa Aesar (Johnson Matthey Company) 
and were used without further purification. HPLC analysis: all target compounds (i.e., assessed in 
biological assays) were ≥95% pure by HPLC, confirmed via UV detection (λ = 254 nm). Analytical 
reversed-phase HPLC was conducted using a Kinetex EVO C18 column (5 μm, 150 mm × 4.6 mm, 
Phenomenex, Inc.). Compounds were dissolved in acetonitrile or methanol, and injected through a 20 
μl loop. Eluent A was water and eluent B was CH3CN; after 5 min at 25% B, a gradient was formed 
from 25% to 75% of B in 5 min and held at 75% of B for 10 min; flow rate was 1 mL/min. For 
compound 9, a different gradient profile of mobile phase was used: after 5 min at 10% B, a gradient 
was formed from 10% to 25% of B in 5 min and then from 25% to 75% of B in the following 2.5 min 
and held at 75% of B for 7.5 min; flow rate was 1 mL/min. The different method was used since 9 
was the only target compound bearing an alkyl group (a methyl group) as R2 substituent (Table 2), 
while all the other compounds possess an aromatic group in that position. The ethyl 2,4-
dioxobutanoate derivatives (29a-d) were prepared as previously reported by our group.50 Ethyl 1-
phenyl-5-(4-hydroxyphenyl)-1H-pyrazole-3-carboxylate 30b, ethyl 1-methyl-5-(4-hydroxyphenyl)-
1H-pyrazole-3-carboxylate 30c, ethyl 1-(4-chlorophenyl)-5-(4-hydroxyphenyl)-1H-pyrazole-3-
carboxylate 30e, and ethyl 1-phenyl-5-(3-hydroxyphenyl)-1H-pyrazole-3-carboxylate 30n with the 
corresponding carboxylic acids 31b, 31c, 31e, and 31n respectively, are described in our previously 
published work.50  
General procedure for the synthesis of 1,5-diphenylpyrazole-3-carboxamides (6-29). To a 
solution of the appropriate carboxylic acid (1.14 mmol) in dry DMF (10 mL), 1-[3-(dimethylamino)-
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propyl]-3-ethylcarbodiimide (EDCI, 1.70 mmol) and 1-hydroxybenzotriazole (HOBt, 1.70 mmol) 
were added and the reaction was stirred at room temperature for 10 min before adding the suitable 
amine (1.36 mmol) and the stirring continued for 16 h. The solvent was evaporated under reduced 
pressure and the residue was dissolved in ethyl acetate (30 mL), washed with aqueous bicarbonate 
(10 mL), water (10 mL) and brine (10 mL). The mixture was concentrated and purified by silica gel 
column chromatography using as eluent an appropriate mixture of ethyl acetate and petroleum ether. 
(5-(4-(Benzyloxy)phenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-
yl)methanone (6). White solid: yield 68%; mp 170 °C; 1H NMR (200 MHz, DMSO-d6): δ 8.39 (d, J 
= 4.6 Hz, 2H), 7.46-7.32 (m, 10H), 7.20(d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 6.89 (s, 1H), 
6.67 (t, J = 5 Hz, 1H), 5.09 (s, 2H), 4.04 (m, 2H), 3.81 (m, 6H). MS (ESI) 517.2 [M+H]+. Anal. 
(C31H28N6O2) C, H, N. HPLC analysis: retention time = 13.884 min; peak area, 99% (254 nm). 
5-(4-(Benzyloxy)phenyl)-1-phenyl-N-(2-(4-(pyrimidin-2-yl)piperazin-1-yl)ethyl)-1H-pyrazole-
3-carboxamide (7). White solid: yield 60%; mp 152 °C; 1H NMR (200 MHz, DMSO-d6): δ 8.34 (d, 
2H, J = 4.8 Hz), 8.25 (t, 1H), 7.38-7.45 (m, 10H), 7.18 (d, 2H, J = 8.6 Hz), 6.98 (d, 2H, J = 8.6 Hz), 
6.92 (s, 1H), 6.64 (t,1H, J = 5 Hz), 5.09 (s, 2H), 3.71 (m, 4H), 3.42 (m, 2H), 3.22 (m, 6H). MS (ESI) 
560.6 [M+H]+. Anal. (C33H33N7O2) C, H, N. HPLC analysis: retention time = 13.423 min; peak area, 
98% (254 nm). 
(5-(4-Hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone 
(8). White solid: yield 58%; mp 241 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.86 (bs, 1H), 8.39 (d, 
2H, J = 4.6 Hz), 7.42-7.35 (m, 5H), 7.04 (d, 2H, J = 8.6 Hz), 6.82 (s, 1H), 6.72 (d, 2H, J = 8.8 Hz), 
6.68-6.66 (m, 1H), 4.14-4.08 (m, 2H), 3.84-3.71 (m, 6H). MS (ESI) 427.2 [M+H]+. Anal. 
(C24H22N6O2) C, H, N. HPLC analysis: retention time = 11.141 min; peak area, 95% (254 nm). 
(5-(4-Hydroxyphenyl)-1-methyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone 
(9). White solid: yield 30%; mp 209 °C; 1H NMR (400 MHz, DMSO-d6): δ 9,80 (bs, 1H), 8.39 (d, 
2H, J = 4.8 Hz), 7.37(d, 2H, J = 8.4 Hz), 6.87 (d, 2H, J = 8,4 Hz), 6.74 (t, 1H, J = 4.8 Hz), 6.60 (s, 
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1H), 4.06-4.04 (m, 2H), 3.86 (s, 3H), 3.82-3.78 (m, 4H), 3.71-3.69 (m, 2H). MS (ESI) 365.1 [M+H]+. 
Anal. (C19H20N6O2) C, H, N. HPLC analysis: retention time = 11.448 min; peak area, 96% (254 nm). 
(5-(3-Hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone 
(10). White solid: yield 25%; mp 122 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.73 (bs, 1H), 8.39 (d, 
2H, J = 4.0 Hz), 7.46-7.41 (m, 3H), 7.36-7.31 (m, 2H), 7.16 (t, 1H, J = 4.2 Hz,), 6.88 (s, 1H), 6.77-
6.64 (m, 4H), 4.10-4.06 (m, 2H), 3.84-3.71 (m, 6H). MS (ESI) 427.2 [M+H]+. Anal. (C24H22N6O2) 
C, H, N. HPLC analysis: retention time = 11.330 min; peak area, 96% (254 nm). 
(5-(4-Hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-phenylpiperazin-1-yl)methanone (11). 
White solid: yield 25%; mp 190 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.78 (bs, 1H), 7.46-7.42 (m, 
3H), 7.34-7.29 (m, 2H), 7.22-7.19 (m, 2H), 7.05 (d, 2H, J = 8.6 Hz), 6.98-6.94 (m, 2H), 6.83 (s, 1H), 
6.80-6.78 (m, 1H), 6.70 (d, 2H, J = 8.6 Hz), 4.16-4.11 (m, 2H), 3.84-3.78 (m, 2H), 3.29-3.17 (m, 4H). 
MS (ESI) 425.2 [M+H]+. Anal. (C26H24N4O2) C, H, N. HPLC analysis: retention time = 12.327 min; 
peak area, 99% (254 nm). 
(5-(4-Hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(4-methylpiperazin-1-yl)methanone (12). 
White solid: yield 25%; mp 198 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.82 (bs, 1H), 7.44-7.39 (m, 3H), 7.32-
7.27 (m, 2H), 7.04 (d, 2H, J = 8.6 Hz), 6.77 (s, 1H), 6.71 (d, 2H, J = 8.6 Hz), 4.01-3.92 (m, 2H), 3.65-3.61 (m, 
2H), 2.49 (s, 3H), 2.37-2.34 (m, 2H), 2.25-2.19 (s, 2H). MS (ESI) 363.2 [M+H]+. Anal. (C21H22N4O2) C, H, N. 
HPLC analysis: retention time = 12.972 min; peak area, 99% (254 nm). 
(5-(4-Hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)(morpholino)methanone (13). White solid: 
yield 28%; mp 227 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.85 (bs, 1H), 7.45-7.41 (m, 5H), 7.04 (d, 
2H, J = 8.8 Hz), 6.80 (s, 1H), 6.71 (d, 2H, J = 8.6 Hz), 4.03-3.98 (m, 2H), 3.64 (s, 6H). MS (ESI) 
350.1 [M+H]+. Anal. (C20H19N3O3) C, H, N. HPLC analysis: retention time = 9.682 min; peak area, 
97% (254 nm). 
(4-Benzylpiperazin-1-yl)(5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)methanone (14). 
White solid: yield 40%; mp 169 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.78 (bs, 1H), 7.43-7.38 (m, 3H), 7.33-
7.26 (m, 7H), 7.03 (d, 2H, J = 8.4 Hz), 6.76 (s, 1H), 6.71 (d, 2H, J = 8.8 Hz), 3.98-3.93 (m, 2H), 3.67-3.62 (m, 
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2H), 3.51 (s, 2H), 2.50-2.41 (m, 4H). MS (ESI) 439.2 [M+H]+. Anal. (C27H26N4O2) C, H, N. HPLC analysis: 
retention time = 11.909 min; peak area, 98% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazol-3-yl)methanone (15). 
White solid: yield 20%; mp 112 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.78 (bs, 1H), 7.44-7.38 (m, 
3H), 7.29-7.25 (m, 4H), 7.18-7.16 (m, 3H), 7.04 (d, 2H, J = 8.4 Hz), 6.73 (s, 1H), 6.72 (d, 2H, J = 
8.4 Hz), 4.60 (d, 1H, J = 14 Hz), 4.48 (d, 1H, J = 12.4 Hz), 3.07 (t, 1H, J =13.2 Hz), 2.69 (t, 1H, J = 
13.2 Hz), 2.54-2.50 (m, 2H), 1.81-1.78 (m, 1H), 1.67-1.58 (m, 2H), 1.18-1.11 (m, 2H). MS (ESI) 
438.2 [M+H]+. Anal. (C28H27N3O2) C, H, N. HPLC analysis: retention time = 13.132 min; peak area, 
95% (254 nm). 
N-(1-Benzylpiperidin-4-yl)-5-(4-hydroxyphenyl)-1-phenyl-1H-pyrazole-3-carboxamide (16). 
White solid: yield 20%; mp 200 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.85 (bs, 1H), 8.03 (d, 1H, J 
= 8.0 Hz), 7.45-7.40 (m, 3H), 7.35-7.27 (m, 7H), 7.03 (d, 2H, , J = 8.6 Hz), 6.85 (s, 1H), 6.70 (d, 2H, 
J = 8.4 Hz), 3.83-3.78 (m, 1H), 3.45 (s, 2H), 2.81 (d, 2H, J = 12.2 Hz), 2.10-1.98 (m, 2H), 1.69-1.63 
(m, 4H). MS (ESI) 453.2 [M+H]+. Anal. (C28H28N4O2) C, H, N. HPLC analysis: retention time = 
10.076 min; peak area, 98% (254 nm). 
5-(4-Hydroxyphenyl)-1-phenyl-N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]-1H-pyrazole-3-
carboxamide (17). White solid: yield 20%; mp 217 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.86 (bs, 1H), 
8.34 (d, 2H, J = 4.6 Hz), 8.19 (t, 1H, J = 4.6 Hz), 7.45-7.40 (m, 3H), 7.35-7.30 (m, 2H), 7.04 (d, 2H, J = 8.4 
Hz), 6.85 (s, 1H), 6.70 (d, 2H, J = 8.8 Hz), 6.63 (t, 1H, J = 5.0 Hz), 3.73-3.68 (m, 4H), 3.42-3.32 (m, 6H), 
2.52-2.49 (m, 2H, J = 5.0 Hz). MS (ESI) 470.2 [M+H]+. Anal. (C26H27N7O2) C, H, N. HPLC analysis: retention 
time = 10.159 min; peak area, 98% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)methanone (18). White 
solid: yield 20%; mp 46 °C; 1H NMR (200 MHz, DMSO-d6): δ 7.46-7.21 (m, 5H), 7.33-7.19 (m, 9H), 6.92 (s, 
1H), 4.61 (d, 1H, J = 14 Hz), 4.50 (d, 1H, J = 12.4 Hz), 3.07-2.72 (m, 2H), 2.54-2.49 (m, 2H), 1.85-1.80 (m, 
1H), 1.65-1.59 (m, 2H), 1.17-1.11 (m, 2H). MS (ESI) 456.18 [M+H]+. Anal. (C28H26ClN3O) C, H, N. HPLC 
analysis: retention time = 15.996 min; peak area, 96% (254 nm). 
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(4-Benzylpiperidin-1-yl)(1,5-diphenyl-1H-pyrazol-3-yl)methanone (19). White solid: yield 22%; 
mp 131 °C; 1H NMR (400 MHz, DMSO-d6): δ 7.45-7.16 (m, 15H), 6.88 (s, 1H), 4.42 (d, 1H, J = 14 
Hz), 4.68 (d, 1H, J = 14 Hz), 3.22 (t, 1H, J = 13.4 Hz), 3.18 (t, 1H, J = 13.2 Hz), 1.98-1.94 (m, 1H), 
2.58-2.56 (m, 2H), 1.75-1.65 (m, 2H), 1.55-1.22 (m, 2H).MS (ESI) 422.2 [M+H]+. Anal. (C28H27N3O) 
C, H, N. HPLC analysis: retention time = 14.849 min; peak area, 98% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-
yl)methanone (20). White solid: yield 25%; mp 128 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.79 (bs, 1H), 
7.27-7.16 (m, 6H), 7.04 (d, 2H, J = 8.8 Hz), 6.96 (d, 2H, J = 8.8 Hz), 6.72 (s, 1H), 6.71-6.70 (m, 3H), 4.61 (d, 
1H, J = 12.8 Hz), 4.47 (d, 1H, J = 12.8 Hz), 3.77 (s, 3H), 3.05 (t, 1H, J = 12.4 Hz), 2.70 (t, 1H, J = 11.6 Hz), 
2.54-2.50 (m, 2H), 1.85-1.79 (m, 1H), 1.67-1.57 (m, 2H), 1.16-1.08 (m, 2H). MS (ESI) 468.2 [M+H]+. Anal. 
(C29H29N3O3) C, H, N. HPLC analysis: retention time = 13.078 min; peak area, 95% (254 nm). 
(4-Benzylpiperidin-1-yl)(1-(4-chlorophenyl)-5-(4-hydroxyphenyl)-1H-pyrazol-3-yl)methanone 
(21). White solid: yield 30%; mp 95 °C; 1H NMR (400 MHz, DMSO-d6): δ 9.83 (bs, 1H), 7.47 (d, 
2H, J = 9.5.0 Hz), 7.24 (d, 2H, J = 9.6 Hz), 7.19-7.15 (m, 5H), 7.02 (d, 2H, J = 8.4 Hz), 6.72 (d, 2H, 
J = 8.4), 6.70 (s, 1H), 4.55-4.44 (m, 2H), 3.08 (t, 1H, J = 12.2 Hz), 2.75 (t, 1H, J = 11.8 Hz), 2.50-
2.48 (m, 2H), 1.88-1.85 (m, 1H), 1.65-1.54 (m, 2H), 1.18-1.15 (m, 2H). MS (ESI) 471.1 [M+H]+. 
Anal. (C28H26ClN3O2) C, H, N. HPLC analysis: retention time = 13.757 min; peak area, 95% (254 
nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(p-tolyl)-1H-pyrazol-3-yl)methanone (22). 
White solid: yield 45%; mp 126 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.80 (bs, 1H), 7.24-7.17 (m, 
9H), 7.05 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J = 8.4 Hz), 6.69 (s, 1H), 4.56-4.48 (m, 2H), 3.08 (t, 1H, 
J = 11.8 Hz), 2.80 (t, 1H, J = 12.0 Hz), 2.50-2.38 (m, 2H), 2.32 (s, 3H), 1.89-1.85 (m, 3H), 1.17-1.15 
(m, 2H). MS (ESI) 451.2 [M+H]+. Anal. (C29H29N3O2) C, H, N. HPLC analysis: retention time = 
13.518 min; peak area, 98% (254 nm). 
(1-Benzyl-5-(4-hydroxyphenyl)-1H-pyrazol-3-yl)(4-benzylpiperidin-1-yl)methanone (23). 
White solid: yield 48%; mp 84 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.90 (bs, 1H), 7.29-7.15 (m, 
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10H), 7.02-6.79 (m, 4H), 6.55 (s, 1H), 5.34 (s, 2H), 4.62-4.35 (m, 2H), 3.13-2.93 (m, 1H), 2.74-2.55 
(m, 1H), 2.54 (m, 2H), 1.92-1.73 (m, 1H), 1.72-1.48 (m, 2H), 1.25-1.02 (m, 2H). MS (ESI) 452.2 
[M+H]+. Anal. (C29H29N3O2) C, H, N. HPLC analysis: retention time = 13.198 min; peak area, 100% 
(254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-phenethyl-1H-pyrazol-3-yl)methanone (24). 
White solid: yield 58%; mp 70 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.92 (bs, 1H), 7.29-7.16 (m, 
8H), 7.05 (d, 2H, J = 8.4 Hz), 6.98-6.94 (m, 2H), 6.80 (d, 2H, J = 8.4 Hz), 6.39 (s, 1H), 4.47-4.40 
(m, 2H), 4.25 (t, 2H, J = 7.0 Hz), 2.99 (t, 2H, J = 7.0 Hz), 2.74-2.54 (m, 4H), 1.99-1.96 (m, 1H), 
1.72-1.52 (m, 2H), 1.21-1.05 (m, 2H). MS (ESI) 466.2 [M+H]+. Anal. (C30H31N3O2) C, H, N. HPLC 
analysis: retention time = 13.374 min; peak area, 98% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(3-phenylpropyl)-1H-pyrazol-3-yl)methanone 
(25). White solid: yield 55%; mp 67 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.94 (bs, 1H), 7.27-7.06 
(m, 12H), 6.85 (d, 2H, J = 8.4 Hz), 6.47 (s, 1H), 4.70-4.59 (m, 2H), 4.07 (t, 2H, J = 6.8), 3.16-2.98 
(m, 1H), 2.78-2.68 (m, 1H), 2.55-2.46 (m, 4H), 2.11-1.95 (m, 2H), 1.91-1.78 (m, 1H), 1.77-1.51 (m, 
2H), 1.23-1.18 (m, 2H). MS (ESI) 480.2 [M+H]+. Anal. (C31H33N3O2) C, H, N. HPLC analysis: 
retention time = 13.835 min; peak area, 99% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(3-methylbenzyl)-1H-pyrazol-3-yl)methanone 
(26). White solid: yield 50%; mp 70 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.81 (bs, 1H), 7.24-7.17 
(m, 9H), 6.84-6.80 (m, 4H), 6.54 (s, 1H), 5.29 (s, 2H), 4.50-4.42 (m, 2H), 3.20-2.98 (m, 1H), 2.78-
2.56 (m, 1H), 2.52-2.48 (m, 2H), 2.21 (s, 3H), 1.98-1.42 (m, 3H), 1.21-1.05 (m, 2H). MS (ESI) 466.2 
[M+H]+ . Anal. (C30H31N3O2) C, H, N. HPLC analysis: retention time = 13.534 min; peak area, 99% 
(254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(4-methylbenzyl)-1H-pyrazol-3-yl)methanone 
(27). White solid: yield 68%; mp 160 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.91 (bs, 1H), 7.28-7.07 (m, 9H), 
6.89-6.80 (m, 4H), 6.53 (s, 1H), 5.29 (s, 2H), 4.58-4.41 (m, 2H), 3.18-2.98 (m, 1H), 2.79-2.58 (m, 1H), 2.54-
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2.49 (m, 2H), 2.23 (s, 3H), 1.98-1.52 (m, 3H), 1.21-1.04 (m, 2H). MS (ESI) 466.2 [M+H]+. Anal. (C30H31N3O2) 
C, H, N. HPLC analysis: retention time = 13.595 min; peak area, 98% (254 nm). 
(4-Benzylpiperidin-1-yl)(1-(3,5-dimethylbenzyl)-5-(4-hydroxyphenyl)-1H-pyrazol-3-
yl)methanone (28). White solid: yield 78%; mp 74 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.91 (bs, 
1H), 7.27-7.15 (m, 7H), 6.87-6.81 (m, 3H), 6.59-6.53 (m, 3H), 5.24 (s, 2H), 4.57-4.41 (m, 2H), 3.20-
2.99 (m, 1H), 2.79-2.60 (m, 1H), 2.55-2.48 (m, 2H), 2.17 (s, 6H), 1.93-1.50 (m, 3H), 1.22-1.05 (m, 
2H). MS (ESI) 480.2 [M+H]+. Anal. (C31H33N3O2) C, H, N. HPLC analysis: retention time = 14.028 
min; peak area, 99% (254 nm). 
(4-Benzylpiperidin-1-yl)(5-(4-hydroxyphenyl)-1-(naphthalen-1-ylmethyl)-1H-pyrazol-3-
yl)methanone (29). White solid: yield 55%; mp 122 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.98 (bs, 
1H), 7.99-7.85 (m, 3H), 7.54-7.13 (m, 10H), 6.81-6.73 (m, 3H), 6.60 (s, 1H), 5.83 (s, 2H), 4.47-4.42 
(m, 2H), 3.21-3.11 (m, 1H), 2.71-2.69 (m, 1H), 2.54-2.51 (m, 2H), 1.93-1.50 (m, 3H), 1.22-1.04 (m, 
2H). MS (ESI) 502.2 [M+H]+. Anal. (C33H31N3O2) C, H, N. HPLC analysis: retention time = 13.888 
min; peak area, 98% (254 nm). 
General procedure for the synthesis of ethyl 1,5-diphenylpyrazole-3-carboxylates (30a-p). A 
mixture of 2,4-dioxobutanoate (6.3 mmol) and appropriate hydrazine (7.5 mmol) in absolute EtOH 
(30 mL) was stirred at 80 °C for 5 h. The solvent was removed under reduced pressure after the 
reaction had reached completion. Then the residue was purified by column chromatography on silica 
gel via elution with an appropriate mixture of ethyl acetate and petroleum ether to give the desired 
product. 
Ethyl 5-[4-(benzyloxy)phenyl]-1-phenyl-1H-pyrazole-3-carboxylate (30a). White solid: yield 
70%; mp 124-125 °C; 1H NMR (200 MHz, DMSO-d6) δ 7.33-7.45 (m, 10H), 7.18 (d, 2H, J = 8.8 
Hz), 7.03 (d, 2H, J = 8.4 Hz), 6.96 (s, 1H), 5.09 (s, 2H), 4.32 (q, J = 7.0 Hz, 2H), 1.31 (t, 3H, J = 7.0 
Hz). MS (ESI) 392.2 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazole-3-carboxylate (30d). White solid: 
yield 67%; mp 177-178 °C; 1H NMR (200 MHz, DMSO-d6) δ 9.75 (bs, 1H), 7.25 (d, 2H, J = 9 Hz), 
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7.04 (d, 2H, J = 8.6 Hz,), 7.00 (d, 2H, J = 9.2 Hz,), 6.88 (s, 1H), 6.71 (d, 2H, J = 8.6 Hz), 4.28 (q, 
2H, J = 7 Hz), 3.78 (s, 3H), 1.30 (t, 3H, J = 7 Hz). MS (ESI) 339.1 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(p-tolyl)-1H-pyrazole-3-carboxylate (30f). White solid: yield 62%; 
mp 199-200 °C; 1H NMR (200 MHz, DMSO-d6) δ 9.82 (bs, 1H), 7.22 (d, 2H, J = 8.8 Hz), 7.02 (d, 
2H, J = 8.6 Hz,), 6.95 (d, 2H, J = 8.8 Hz,), 6.88 (s, 1H), 6.67 (d, 2H, J = 8.6 Hz), 4.30 (q, 2H, J = 7 
Hz), 2.28 (s, 3H), 1.30 (t, 3H, J = 7 Hz). MS (ESI) 322.1 [M+H]+. 
Ethyl 1-benzyl-5-(4-hydroxyphenyl)-1H-pyrazole-3-carboxylate (30g). White solid: yield 50%; mp 
79-81 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.87 (bs, 1H), 7.27-7.22 (m, 5H), 6.99-6.95 (m, 2H), 
6.85-6.80 (m, 3H), 5.42 (s, 2H), 4.28 (q, 2H, J = 7.2 Hz), 1.29 (t, 3H, J = 7.0 Hz). MS (ESI) 323.1 
[M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(2-phenylethyl)-1H-pyrazole-3-carboxylate (30h). Light yellow 
solid; yield 40%; mp 190-192 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.98 (bs, 1H), 7.23-7.20 (m, 
2H), 7.07 (m, 5H), 6.82-6.77 (m, 2H), 6.66 (s, 1H), 4.34-4.27 (m, 4H), 3.04 (t, 2H, J = 8.3 Hz), 1.30 
(t, 2H, J = 7.0 Hz). MS (ESI) 337.1 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(3-phenylpropyl)-1H-pyrazole-3-carboxylate (30i). Light yellow 
solid; yield 48%; mp 126-128 °C. 1H NMR (200 MHz, DMSO-d6): δ 9.95 (bs, 1H), 7.25-7.05 (m, 
7H), 6.83-6.79 (m, 2H), 6.69 (s, 1H), 4.26 (q, 2H, J = 7.0 Hz), 4.11 (t, 2H, J = 7.3 Hz), 2.58 (t, 2H, J 
= 8.3 Hz), 2.10-1.92 (m, 2H), 1.27 (t, 3H, J = 7.0 Hz). MS (ESI) 351.2 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(3-methylbenzyl)-1H-pyrazole-3-carboxylate (30j). White solid: 
yield 81%; mp 173-175 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.96 (bs, 1H), 7.26-7.00 (m, 4H), 
6.85-6.69 (m, 5H), 5.37 (s, 2H), 4.28 (q, 2H, J = 7.2), 2.23 (s, 1H), 1.29 (t, 3H, J = 7.2 Hz). MS (ESI) 
337.1 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(4-methylbenzyl)-1H-pyrazole-3-carboxylate (30k). White solid: 
yield 80%; mp 147-148 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.97 (s, 1H), 7.24 (d, 2H, J = 8.4), 
7.52 (d, 2H, J = 7.8 Hz), 6.84-6.79 (m, 5H), 5.36 (s, 2H), 4.27 (q, 2H, J = 7.2), 2.24 (s, 3H), 1.28 (t, 
3H, J = 7.2 Hz). MS (ESI) 337.1 [M+H]+. 
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Ethyl 1-(3,5-dimethylbenzyl)-5-(4-hydroxyphenyl)-1H-pyrazole-3-carboxylate (30l). White 
solid: yield 64%; mp 162-163 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.98 (bs, 1H), 7.26-7.21 (m, 
2H), 6.88-6.79 (m, 4H), 6.56 (s, 2H), 5.31 (s, 2H), 4.28 (q, 2H, J = 7.0 Hz), 2.18 (s, 6H), 1.28 (t, 3H, 
J = 7.0 Hz). MS (ESI) 351.2 [M+H]+. 
Ethyl 5-(4-hydroxyphenyl)-1-(1-naphthylmethyl)-1H-pyrazole-3-carboxylate (30m). White 
solid: yield 54%; mp 215-216 °C; 1H NMR (200 MHz, DMSO-d6): δ 9.95 (bs, 1H), 7.97-7.84 (m, 
3H), 7.57-7.24 (m, 5H), 6.89 (s, 1H), 6.79-6.69 (m, 3H), 5.91 (s, 2H), 4.28 (q, 2H, J = 7.0 Hz), 1.28 
(t, 3H, J = 7.0 Hz). MS (ESI) 373.2 [M+H]+. 
Ethyl 1,5-diphenyl-1H-pyrazole-3-carboxylate (30o). White solid: yield 64%; mp 82-84 °C; 1H 
NMR (200 MHz, DMSO-d6): δ 7.46-7.28 (m, 10H), 7.13 (s, 1H), 4.34 (q, 2H, J = 7.4 Hz), 1.32 (t, 
3H, J = 7.0 Hz). MS (ESI) 293.1 [M+H]+. 
Ethyl 5-(4-chlorophenyl)-1-phenyl-1H-pyrazole-3-carboxylate (30p). Light yellow solid; yield 
55%; mp 95-97 °C; 1H NMR (200 MHz, DMSO-d6): δ 7.47-7.25 (m, 9H), 7.17 (s, 1H), 4.34 (q, 2H, 
J = 8.0 Hz), 1.32 (t, 3H, J = 7.2 Hz). MS (ESI) 327.1 [M+H]+. 
General procedure for the synthesis of 1,5-diphenylpyrazole-3-carboxylic acids (31a-p). To a 
solution of the esters 30a-p (2.0 mmol) in ethanol (30 mL) was added aqueous sodium hydroxide 
(10%, 8 mL). The resulting mixture was stirred at 60 °C for 4 h. The solvent was evaporated under 
reduced pressure, and the residue was acidified with 10% hydrochloric acid at 0 °C. The precipitate 
thus formed was collected by filtration, washed with water, and dried under vacuum to give the 
desired carboxylic acid. 
5-[4-(Benzyloxy)phenyl]-1-phenyl-1H-pyrazole-3-carboxylic acid (31a). White solid: yield 80%; 
mp 168-169 °C; 1H NMR (200 MHz, DMSO-d6) δ 12.3 (bs, 1H), 7.47-7.34 (m, 10H), 7.17 (d, 2H, J 
= 8.8 Hz), 7.01-6.97 (m, 3H), 5.09 (s, 2H). MS (ESI) 371.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid (31d). White solid: 
yield 84%; mp 197-198 °C; 1H NMR (200 MHz, DMSO-d6) δ 12.80 (bs, 1H), 9.85 (bs, 1H), 7.23 (d, 
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2H, J = 9 Hz), 7.4 (d, 2H, J = 8.6 Hz), 7.0 (d, J = 9.2 Hz, 2H), 6.88 (s, 1H), 6.71 (d, 2H, J = 8.6 Hz), 
3.78 (s, 3H). MS (ESI) 311.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(p-tolyl)-1H-pyrazole-3-carboxylic acid (31f). White solid: yield 75%; 
mp 234 °C; 1H NMR (200 MHz, DMSO-d6) δ 12.80 (bs, 1H), 9.85 (bs, 1H), 7.23 (d, 2H, J = 8.8 Hz), 
7.16 (d, 2H, J = 8.4 Hz), 7.05 (d, 2H, J = 8.8 Hz), 6.89 (s, 1H), 6.71 (d, 2H, J = 8.8 Hz), 2.33 (s, 3H). 
MS (ESI) 294.1 [M+H]+. 
1-Benzyl-5-(4-hydroxyphenyl)-1H-pyrazole-3-carboxylic acid (31g). White solid: yield 80%; mp 
244-246 °C; 1H NMR (200 MHz, DMSO-d6): δ 12.89 (bs, 1H), 9.87 (bs, 1H), 7.31-7.21 (m, 5H), 
7.01-6.96- (m, 2H), 6.84-6.80 (m, 2H), 6.73 (s, 1H), 5.39 (s, 2H). MS (ESI) 295.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(2-phenylethyl)-1H-pyrazole-3-carboxylic acid (31h). White solid: yield 
87%; mp 198-199 °C; 1H NMR (200 MHz, DMSO-d6): δ 13.11 (bs, 1H), 9.98 (bs, 1H), 7.23-7.20 (m, 
2H), 7.06-6.97 (m, 5H), 6.82-6.77 (m, 2H), 6.60 (s, 1H), 4.28 (t, 2H, J = 6.9 Hz), 3.04 (t, 2H, J = 7.8 
Hz). MS (ESI) 309.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(3-phenylpropyl)-1H-pyrazole-3-carboxylic acid (31i). White solid: 
yield 75%; mp 196-198 °C; 1H NMR (200 MHz, DMSO-d6): δ 13.10 (bs, 1H), 9.95 (bs, 1H), 7.33-
7.16 (m, 7H), 6.97-6.92 (m, 2H), 6.71 (s, 1H), 4.19 (t, 2H, J = 7.2), 2.58 (t, 2H, J = 8.3 Hz), 1.99 (m, 
2H). MS (ESI) 323.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(3-methylbenzyl)-1H-pyrazole-3-carboxylic acid (31j). White solid: 
yield 80%; mp 207-208 °C; 1H NMR (200 MHz, DMSO-d6): δ 12.85 (bs, 1H), 9.20 (bs, 1H), 7.25-
7.02 (m, 4H), 6.85-6.73 (m, 5H), 5.34 (s, 2H), 2.23 (s, 3H). MS (ESI) 309.1 [M+H]+. 
5-(4-Hydroxyphenyl)-1-(4-methylbenzyl)-1H-pyrazole-3-carboxylic acid (31k). White solid: 
yield 88%; mp 242-243 °C; 1H NMR (200 MHz, DMSO-d6): δ 13.20 (bs, 1H), 10.00 (bs, 1H), 7.25-
7.08 (m, 4H), 6.90-6.80 (m, 4H), 6.73 (s, 1H), 5.34 (s, 2H), 2.25 (s, 3H). MS (ESI) 309.1 [M+H]+. 
1-(3,5-Dimethylbenzyl)-5-(4-hydroxyphenyl)-1H-pyrazole-3-carboxylic acid (31l). White solid: 
yield 88%; mp 240-242 °C; 1H NMR (200 MHz, DMSO-d6): δ 12.88 (bs, 1H), 9.81 (bs, 1H), 7.25-
7.20 (m, 4H), 6.88-6.81 (m, 3H), 6.71 (s, 1H), 5.29 (s, 2H), 2.19 (s, 6H). MS (ESI) 323.1 [M+H]+. 
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5-(4-Hydroxyphenyl)-1-((naphthalen-1-yl)methyl)-1H-pyrazole-3-carboxylic acid (31m). White 
solid: yield 90%; mp 251-252 °C; 1H NMR (200 MHz, DMSO-d6): δ 12.85 (bs, 1H), 9.82 (bs, 1H), 
7.99-7.34 (m, 3H), 7.57-7.37 (m, 3H), 7.27-7.23 (m, 2H), 6.82-6.69 (m, 4H), 5.88 (s, 2H). MS (ESI) 
345.1 [M+H]+. 
1,5-Diphenyl-1H-pyrazole-3-carboxylic acid (31o). White solid: yield 85%; mp 182-183 °C; 1H 
NMR (200 MHz, DMSO-d6): δ 12.99 (bs, 1H), 7.40-7.17 (m, 10H), 6.74 (s, 1H). MS (ESI) 265.1 
[M+H]+. 
5-(4-Chlorophenyl)-1-phenyl-1H-pyrazole-3-carboxylic acid (31p). White solid: yield 75%; mp 
>300 °C; 1H NMR (200 MHz, DMSO-d6): δ 12.95 (bs, 1H), 7.41-7.17 (m, 9H), 6.75 (s, 1H). MS 
(ESI) 299.1 [M+H]+. 
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